Study Findings from Research Institute Broaden Understanding of Gene Therapy (Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy)
The news reporters obtained a quote from the research from
According to the news reporters, the research concluded: "These results indicate that the miR223 promoter as an internal promoter within SIN gene therapy vectors is able to efficiently correct the CGD phenotype with negligible activity in hematopoietic progenitors, thereby limiting the risk of insertional oncogenesis and development of clonal dominance."
For more information on this research see: Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy. Human Gene Therapy Methods, 2013;24(3):151-9 (see also Biotechnology).
Our news correspondents report that additional information may be obtained by contacting
Keywords for this news article include: Biotechnology,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Neighbor Warns Chris Brown to Stay Off His Property
- Venezuelan Officials Banned From Traveling in U.S.
- Homeowners More Satisfied With Mortgage Servicers
- WWE Showing Off Its Muscles
- As Jobs Market Strengthens, Many Don't Feel It
- Ford Tremor: Easy to Park, Hard to Pay For
- Adrienne Bailon Disses Ex-Lover Rob Kardashian
- Target Taps Pepsi Exec as New CEO
- Hispanic Arts Leaders Unite Across the Border
- Islamic State Fights for Control of Syrian Oil Wealth